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Summary We have investigated the possibility that structural alterations of the 'nuclear' oncogene family
(c-myc, N-myc, L-myc, fos, myb and p53) leading to aberrant expression might, as in several other tumour
types, play a role in the multi-stage development of tumorigenesis in the human thyroid follicular cell. Direct
analysis of expression by slot and Northern blot RNA hybridisation showed that normal thyroid expresses
surprisingly high levels offos, and to a lesser extent c-myc. c-myc expression was markedly increased in all
tumours, both benign and malignant, but no increase was seen in any other nuclear oncogene. fis expression
was reduced specifically in one type of malignant tumour - follicular carcinoma - in inverse correlation with
differentiation. Southern blot analysis showed no evidence of rearrangement or amplification of c-myc, or of
any other 'nuclear' oncogene in any thyroid tumour. We conclude that there is no evidence that a primary
abnormality of these genes plays a role in thyroid follicular cell tumorigenesis and suggest that the observed
changes in expression can be adequately explained as secondary consequences of the tumour phenotype.
The so-called 'nuclear' oncogenes c-myc, N-myc, L-myc, myb,
fos, and p53 code for a group of related oncoproteins which
share the properties of nuclear localisation and binding to
nuclear matrix/DNA, several members of which have been
implicated in control of gene transcription and cell prolifera-
tion (for review see Alitalo et al., 1987). In vitro studies have
shown that experimentally induced overexpression of most
members of the group can synergise with activated (mutated)
ras oncogenes to bring about malignant transformation of
primary (mainly mesenchymal) cells (Weinberg, 1985). In
vivo, in both human and experimental tumours, deregulated
expression of these genes has been found as one of several
presumed co-operating genetic lesions - for example c-myc
with N-ras in promyelocytic leukaemia (Land et al., 1983)
and with K-ras in radiation-induced rat skin tumours (Sawey
et al., 1987). In addition, overexpression, particularly of the
myc family, is a consistent feature of progression to more
advanced malignancy in several tumour types, notably
neuroblastoma (Schwab et al., 1984) and small cell lung
cancer (Nau et al., 1986).
In all cases where overexpression occurs through a primary
defect in the gene locus, two major mechanisms have been
observed (Alitalo et al., 1987): (a) rearrangements due to
chromosome translocation which affect the function of
regulatory elements of the gene; and (b) amplification of the
intact locus, leading to an increased number of otherwise
normal copies of the gene. In thyroid follicular cell tumours
we have recently shown that activation of the ras family of
oncogenes is frequently found, not only in follicular car-
cinomas but also in adenomas (Lemoine et al., 1988 a, b).
Since ras activation therefore appears to be an early (pre-
malignant) event we have begun investigating the nature of
the additional genetic changes which must determine progres-
sion to malignancy and in some cases to anaplastic cancer.
As a first step we have looked for the presence of abnor-
malities of structure (rearrangements or amplification) and of




We analysed the following thyroid follicular cell tumours
(classified according to conventional histopathological
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criteria-Hedinger, 1974): 15 adenomas (8 of macrofollicular,
7 of microfollicular histological pattern); 17 differentiated
carcinomas (5 follicular, 12 papillary); four anaplastic car-
cinomas. All tumours were obtained fresh from surgery,
frozen in liquid nitrogen and stored at -70'C.
DNA extraction
Tumours were homogenised in a Waring blender, and DNA
extracted as described by Kunkel et al. (1977), modified by
the addition of sodium perchlorate (to 1M) after the pro-
teinase K digestion step. DNAs prepared similarly from
peripheral blood leukocytes of normal subjects were used as
controls.
Southern blot analysis
Genomic DNA from tumours and controls was digested with
appropriate restriction enzymes (Table 1), fractionated on
0.7-0.8% agarose gels (Maniatis et al., 1982) and blotted on
to nylon membranes (Hybond, Amersham). Membranes were
hybridised to 32P-labelled probes prepared by the random
primer method (Feinberg & Vogelstein, 1983) and washed to
high stringency (0.1 x SSC, 65°C). To control for variation in
amount of DNA loaded, each membrane was rehybridised
with a second probe, pHPT31 (Brennand et al., 1983),
specific for the 'housekeeping' gene hypoxanthine phos-
phoribosyltransferase (HPRT) to provide an internal stan-
dard in assessing oncogene amplification. The intensity of
autoradiographic bands was quantified by scanning den-
sitometry.
Probes and restriction enzymes
The restriction enzymes used to digest the genomic DNA and
the probes used for hybridisation were chosen so as to cover
the coding sequence of each gene and as much as possible of
the 5' and 3' regions in order to maximise the chances of
detecting rearrangements. The enzymes and probes used for
each gene and the regions of each locus effectively probed are
detailed in Table I.
RNA extraction
Enough tissue was available for RNA extraction on the
following subset of the above tumours: 12 adenomas, four
follicular carcinomas, five papillary carcinomas, one anaplas-
tic carcinoma. In addition, eight samples of normal thyroid
tissue were also analysed. Frozen tissue was crushed in liquid
nitrogen and total cellular RNA extracted by lysis in
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Table I Probes and regions of oncogene loci analysed
Limits of
Restriction Probe Fragment region probed
Gene enzyme (source/ref.) sizes (kb) 5'; 3'
c-myc EcoRi pUC-cDlA 12.5 6.3 kb; 0.6 kb
(a)
N-myc HindIll pNB-1 16.0 5.8 kb ; 4.3 kb
(b)
L-myc EcoRi pL-myclO 10.0 3.7 kb; 0.1 kb
(c) (or 6.6)' (or -3.3 kb)
c-fos EcoRi pc-fos-1 9.0 2.0 kb;4.1 kb
(d)




p53 EcoRl pCD53 3.8, 16.0 2.0 kb; 15 kb
(g)
'A restriction fragment length polymorphism for this locus leads
to two alternative EcoRl fragment sizes; the 6.6 kb fragment trun-
cates the probed region 3.3 kb short of the 3' end of the gene.
t Estimating the 3' end of the gene on the basis of homology with
v-myb. Probes: (a) Rabbitts et al. (1983)/Dr T. Rabbitts, MRC,
Cambridge, UK; (b) Schwab et al. (1983)/American Type Culture
Collection (ATCC); (c) Nau et al. (1985)/Dr J. Varley, ICI Joint
Labs, Leicester, UK; (d) Miller et al. (1984)/ATCC, a 3.3 kb NcoI/
BamHI fragment was used to exclude Alu repeat sequences; (e)
Franchini et al. (1983)/Dr S. Watt, LRF, London, UK; (f) Dr R.
Watson, ICRF, London, UK; (g) Matlashewski et al. (1984)/Dr L.
Crawford, ICRF, London, UK.
guanidinium thiocyanate followed by centrifugation through
caesium chloride (Chirgwin et al., 1979).
Slot blot analysis
RNA was denatured (2.2 M formaldehyde, 65'C, 10 min) and
applied to nitrocellulose membranes in a vacuum slot blot
apparatus (Millipore). For each case, three 4-fold dilutions,
beginning with 41g total RNA, were analysed. In addition,
to control for contaminating DNA, a fourth slot was
included containing 4;g RNA pre-treated with 0.3 M NaOH
(65'C, 1 h). Prehybridisation and hybridisation were carried
out in 50% formamide at 42'C as described (Maniatis et al.,
1982). Blots were washed to high stringency (0.1 x SSC,
65°C).
Northern blot analysis
Ten to 20fig denatured total RNA was electrophoresed
through a 1% agarose/formaldehyde gel in 2.2 M for-
maldehyde in 0.04M MOPS buffer (Maniatis et al., 1982)
and blotted on to nitrocellulose as described (Thomas, 1980).
Hybridisation and washing were as for slot blots.
Results
RNA analysis
Total RNA from tumour and normal thyroid samples was
first analysed by slot blot hybridisation. The level of expres-
sion of each oncogene was compared to that of the
housekeeping gene HPRT, the expression of which can be
assumed to be independent of proliferative rate or neoplastic
phenotype, to control for unavoidable variations in amount
of RNA loaded between samples. Oncogene expression was
also compared with that of thyroglobulin (TG), which is a
highly expressed differentiation marker of normal thyroid.
Finally, all samples were hybridised in parallel with slots
containing 4fig of denatured normal human DNA to control
for differences in specific activity between the various probes.
Simple inspection of the autoradiographs (for a represen-
tative subset of samples see Figure 1) showed that readily
detectable hybridisation signals were obtained, in descending











Figure 1 Slot blot analysis of RNA from normal and neoplastic
thyroid. Three dilutions of each sample (4jg, 1 jig and 0.25jlg
total RNA) were hybridised to the probes indicated (except for
TG where I dilution (0.25pg) only is shown). Representative
examples are shown of normal (Ni, N2), adenomas (ADI, AD2),
papillary carcinomas (PCI, PC2), follicular carcinomas (FC1,
FC2) and a single anaplastic carcinoma (AC). Also included in
each hybridisation is a slot (D) containing 4jsg normal DNA (see
text).
order of magnitude, with TG, fos, HPRT, and c-myc probes
on normal thyroid RNA. c-myc signals were clearly increased
in most tumour samples, both from benign (adenomas) and
malignant tumours. In contrast, fos hybridisation showed no
overall change in any tumour type except for the follicular
carcinomas in which the signal was either reduced (e.g. FC2
in Figure 1) or undetectable (FC1). TG was also markedly
reduced in the latter case and was undetectable in the ana-
plastic carcinoma (AC).
No hybridisation to any sample was detectable with the
N-myc, L-myc, and c-myb probes. (Faint signals were
occasionally observed for p53 in both normal and tumours but
were inconsistent; data not shown.)
To permit accurate comparisons between expression of
different genes, the amount ofradioactivity bound in each slot
was first estimated from the optical density (OD) of the
autoradiographic band by reference to a calibration curve of
OD vs dilution ofa standard sample (not shown), to correct for
film non-linearity. This signal, SR, was then adjusted to take
accountof(i)thelengthLR(kbp)ofprobesequencecomplemen-
tary to thecorrespondingmRNA, whichvariedbetweenprobes,
and (ii) the specific activity of the probe and efficiency of
hybridisation, which varied between analyses. Variable (ii) was
estimated experimentally by inclusion of a DNA-standard slot
(4fig normal DNA) with each hybridisation. The signal from
this was corrected for film calibration to give SD, and for
available probe sequence length, LD (effectively the size of the
whole insert). The estimated amount ofa specific transcript (in
arbitrary units) is therefore given by:
S = SR . LR . SD/LD
or SR X I/SD X LD/LR
The formula showsclearly that whilecomparisons can be made
between cases hybridised at the same time with the sameprobe,
simply by inspection of the autoradiogram, this can be quite
invalid when comparing across different probes or different
hybridisation, since SD and LD /LR cannot be assumed to be
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The values ofS obtained for c-myc andfos in this way were
expressed asaproportion ofthecorrespondingvalueforHPRT
so as to correct for variations in total RNA available for
hybridisation. Theresults(Table II)confirmthegeneral pattern
suggested by Figure 1. Innormal thyroid, thereisahighlevel of
fos transcripts, 4.6 ± 1.7 fold (mean ± s.e.) higher than HPRT,
andalowerabundanceofc-myc,0.09 ± 0.02fold HPRT. While
there is overlap between the groups, benign tumours
(adenomas) showed a very significantly higher abundance of
c-myc than in normal thyroid (c-myc/HPRT ratio 0.55 ± 0.17
compared to 0.09 ± 0.02; P<0.01). Similar high levels were
found in the differentiated malignant tumour groups (follicular
and papillary carcinomas); the single case ofanaplastic cancer
for which RNA was available gave an even higher c-myc signal
but the statistical significance of this cannot be assessed until
furthercases are analysed. There was no statistically significant
change in fos expression except in the follicular carcinomas
which showed a marked decrease in fos/HPRT ratio from
4.6 ± 1.7 in normal to 0.19 ± 0.07 (P<0.001).
Selected cases, including the follicular carcinomas, were
further analysed by Northern blotting. Transcripts of the
expected sizewerefoundforHPRT,fosandc-myc, theintensity
of which correlated well with the signals obtained in the
corresponding slot blots. In particular, Northern analysis
confirmed that the loss offos hybridisation signal in FCl was
not the result of RNA degradation, and that the expected size
transcript detected in normal and other tumour samples was
absent in this tumour (Figure 2).
Genomic analysis
A representative Southern blot, of thefos locus, is shown in
Figure 3. It can be seen that although the absolute intensity
varies from case to case due to inevitable variations in
amount of DNA loaded, the ratio offos to HPRT signals is
not increased in tumour DNA compared to controls. There is
therefore no increase in copy number of thefos gene in these
tumours.
Comparison of the migration of thefos-specific restriction
fragment with that of the size markers (HindIII digest of
phage A ) shows the expected size of 9.0 kbp in both tumours
and controls. There is therefore no evidence of rearrange-
ment or deletion of the fos locus in these tumours.
Comparable Southern blot analysis of normal and thyroid
tumour DNAs using probes for the five other nuclear
oncogenes (c-myc, N-myc, L-myc, myb and p53) also showed
restriction fragments of normal size and abundance in all
tumours in our series.
Discussion
Our data show that, in agreement with two previous studies
(Aasland et al., 1988; Terrier et al., 1988), normal adult
thyroid contains c-myc transcripts readily detectable in total
Table II Expression of c-myc and fos in normal and neoplastic
human thyroid
c-myc/HPRT0 fos/HPRr
Normal thyroid 0.09 + 0.02 4.6 ± 1.7
(n = 8) (0.03-0.25) (1.0-16)
Adenomas 0.55 ± 0.17 8.3 ± 2.9
(n = 12) (0.6-2.0) (0.5-24)
Papillary 0.50 ± 0.18 3.3± 1.3
carcinomas (0.25-1.0) (0.5-8.0)
(n = 5)
















Figure 2 Northern blot analysis of thyroid RNA. One example
each of normal (N1), adenoma (Al) and follicular carcinoma
(Fl) are shown. Replicate aliquots of 10lg total RNA per lane
were hybridised to fos and HPRT probes. Note absence offos
band in Fl. (Size markers: 28S and 18S RNA).




Figure 3 Southern blot analysis of c-fos oncogene in thyroid
tumour DNA. Each lane contains 10 Lg EcoRI digested genomic
DNA. Lanes: (a) normal control (leukocyte DNA); (b) thyroid
adenoma; (c) follicular carcinoma; (d) papillary carcinoma; (e, I)
anaplastic carcinomas. A single 9.0 kb restriction fragment hyb-
ridised to the c-fos probe (solid arrow). Reprobing with the
HPRT probe gave two HPRT-specific bands at 8.2 kb and 7.7 kb
(open arrows). (Size markers shown in kb.)
cellular RNA (a perhaps surprising result in view of its
extremely low level of mitotic activity; Wright & Alison,
1984). In contrast to previous reports, however, we have
observed a marked (6-fold) increase in expression ofc-myc in
benign as well as malignant thyroid tumours. Aasland et al.
(1988) found elevation only in an anaplastic tumour
(although follicular carcinomas were not included) and Ter-
rier et al. (1988) found increased myc to be confined to the
malignant tumours, and indeed to correlate with poor prog-
nosis within this group. The basis for these differences is not
clear, although some aspects of the methodology of the latter
study are difficult to interpret. The reference level to which564 F.S. WYLLIE et al.
expression was compared, for example, is not clear, and both
normal and tumour groups apparently contained samples
showing 'raised' levels. The discordance is important since
our data, unlike those of Terrier et al., do not support a role
for increased c-myc expression in malignant progression.
Cell culture observations of the role of myc in thyrocytes,
in both primary and established cells have shown that the
thyroid mitogens, TSH and EGF, both induce increases in
c-myc transcript abundance (Dere et al., 1985; Reuse et al.,
1986; Colletta et al., 1986) analogous to that seen in fibro-
blasts and lymphocytes following mitogen stimulation (Kelly
et al., 1983; Campisi et al., 1984) which suggests that c-myc
may be an important signal for follicular cell growth.
Experimental evidence for a direct role of myc in follicular
cell transformation is scanty, being limited to the finding that
introduction of a myc expression vector was necessary to
permit full transformation by an activated viral ras gene in
an immortal rat thyroid line (Fusco et al., 1987). There is no
data on primary thyroid cells comparable to that for fibro-
blasts (Land et al., 1983) and Schwann cells (Ridley et al.,
1988).
While our genomic analysis does not entirely exclude struc-
tural changes (such as rearrangements with breakpoints lying
outside the regions probed or small deletions/point mutations
below the resolution of Southern blotting), failure to find
amplification or rearrangement of c-myc, in agreement with
previous studies (Terrier et al., 1988; Aasland et al., 1988),
argues against the involvement of any primary abnormality
of this gene in thyroid tumours. Given the close correlation
of myc amplification with loss of differentiation in several
other human cancers, it was particularly important to exc-
lude this possibility in anaplastic carcinoma of the thyroid,
which was not adequately represented in earlier series.
Our findings for thyroid resemble observations on another
human glandular epithelium, colon (Erisman et al., 1985;
Sikora et al., 1987), in which c-myc expression varies in
relation to proliferative and/or differentiation state and is in
general higher in tumours than normal tissue, again in the
absence of any demonstrable abnormality of the c-myc locus.
We conclude therefore that, as in the colon (Calabretta et
al., 1985), increased c-myc expression in thyroid tumours
most likely reflects the higher proportion of proliferating/less
differentiated cells in tumour compared with normal
epithelium, rather than any causal role in tumorigenesis
per se.
Fos expression was also readily detectable in normal
thyroid, at levels even higher than that of c-myc, but unlike
myc was not increased in any thyroid tumour group. On the
contrary, fos expression was reduced in one class of tumour,
the follicular carcinomas, and moreover was undetectable in
the only widely invasive case of FC in the series (which was
also the least differentiated, as assessed both histologically
and by thyroglobulin expression). These changes are very
unlikely to be due to greater degradation offos mRNA in
these cases, since there was no corresponding fall in abun-
dance of the equally unstable c-myc transcript, and these
samples were not subject to any greater delay before freezing.
Although initial observation of a transient stimulation of
fos expression by mitogens (even more marked than for
c-myc) supported a role for fos in signalling proliferation
(Kruijer et al., 1984), induction of fos has since been
observed in association with cessation of growth accompany-
ing differentiation, e.g. induction of macrophage
differentation in HL60 cells by phorbol esters (Mitchell et al.,
1985) and of neuronal differentiation of PC12 cells by NGF
(Morgan & Curran, 1986). In the thyroid the only data
available are observations on transient induction by TSH,
analogous to that of other mitogens (Colletta et al., 1986)
but since TSH mediates both proliferation and functional/
differentiation responses in thyrocytes, this does not distin-
guish between these two roles. Our finding of relatively high
levels of fos expression in normal thyroid, analogous to
similar findings in several other mitotically inactive cell types
in vivo, notably macrophages (Wagner & Muller, 1986),
together with the loss of expression in the less differentiated
tumours suggests a role in differentiation rather than growth
in the follicular cell.
Since the start of this study, the product of the recently
described oncogene c-jun has been shown to bind to, and act
in concert with, fos protein in regulating gene transcription
(Rauscher et al., 1988). We have analysed a subset of the
original series using a human c-jun probe (Ryseck et al.,
1988) and find that the abundance of c-jun transcripts is
closely similar to that offos and moreover declines in parallel
with fos in the follicular carcinomas (data not shown).
As regards the other nuclear oncogenes, there was no
reproducibly detectable expression of N-myc, L-myc, myb or
p53 mRNA in either normal or tumour samples (although we
cannot totally rule out small increases in tumours, since the
detection limit of the techniques used is not known). Neither
was there any evidence of genomic abnormalities on
Southern analysis. These genes would appear therefore to be
irrelevant to thyroid growth and neoplasia. This provides an
interesting contrast with our recent study of tumours derived
from the other epithelial cell type in the thyroid - the C cell -
which forms a tiny sub-population, distinct both emb-
ryologically and functionally from the follicular cell. C cell
carcinomas showed a high incidence of N-myc expression
which was undetectable in the normal C-cell (Boultwood et
al., 1988).
In conclusion it would appear from our data that there is
little to support a direct role for this group of genes in
thyroid follicular cell cancer. A major objective must now be
to determine the additional genetic events which co-operate
with ras oncogene activation to determine progression in
these tumours. Both ourselves (unpublished data) and others
(Aasland et al., 1988) have found no evidence for
amplification of two other likely candidate genes: c-erbB and
c-erbB2. We are currently exploring the possible role of
anti-oncogenes in this regard.
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